• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

RCT Results: Fresh vs Frozen Strategy for Embryo Transfer?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Data suggests that a freeze-all strategy for embryo transfer may have benefit in the context of PCOS
    • Data for normal cycles are conflicting
  • There is potential benefit to a freezing strategy because it avoids the risk of hyperstimulation – GnRH agonist can be used for triggering final maturation
  • Stormlund et al. (BMJ, 2020) assessed pregnancy rate using a freeze-all strategy with GnRH agonist triggering vs fresh strategy with conventional hCG triggering

METHODS:

  • Multicenter, randomized controlled superiority trial
  • Participants
    • 18 to 39 years
    • Regular menses
    • First, second, or third IVF treatment cycle
  • Interventions
    • Freeze-all group (elective freezing of all embryos): GnRH agonist triggering and single frozen-thawed blastocyst transfer in a subsequent modified natural cycle
    • Fresh transfer group: hCG triggering and single blastocyst transfer in the fresh cycle
  • Study design
    • Randomization on cycle day 2 or 3
    • Analysis was performed as intention-to-treat
  • Primary outcome
    • Ongoing pregnancy rate definition:  Detectable fetal heart beat after eight weeks of gestation
  • Secondary outcomes
    • Live birth rate
    • Positive hCG rate
    • Time to pregnancy
    • Pregnancy related complication (obstetric and neonatal)

RESULTS:

  • 453 women were included
    • Freeze-all: 223 women
    • Fresh: 230 women
  • Ongoing pregnancy rate did not differ significantly between the freeze-all and fresh transfer groups (P=0.76)
    • Freeze-all: 27.8%
    • Fresh: 29.6%
    • Risk ratio (RR) 0.98 (95% CI, 0.87 to 1.10)
  • There was no significant difference in the live birth rate (P=0.83)
    • Freeze-all: 27.4% (61 women)
    • Fresh: 28.7% (66 women)
    • RR 0.98 (95% CI, 0.87 to 1.10)
  • There were no significant differences in positive hCG rate or pregnancy loss
  • There were no significant differences between the 2 groups for the following
    • Severe ovarian hyperstimulation syndrome
    • Obstetric, and neonatal complications
  • Higher mean birth weight associated with frozen transfer (P<0.001)
    • Freeze-all: 3586g
    • Fresh: 3117g
  • Increased risk of prematurity associated with fresh transfer (P=0.01)
    • Freeze-all: 0
    • Fresh: 11.1%
  • Time to pregnancy was longer in the freeze-all group (P<0.001)
    • Freeze-all: 86 days
    • Fresh: 28 days

CONCLUSION:

  • A freeze-all strategy, with GnRH agonist triggering for final oocyte maturation, did not improve pregnancy or live birth rates, compared to a fresh transfer strategy, in women with regular menstrual cycles
  • The authors state

…fresh embryo transfer should be used as the gold standard if no apparent treatment advantage or immediate risk of ovarian hyperstimulation syndrome is present because it is vital for patients not to postpone pregnancy

Learn More – Primary Sources:

Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: multicentre randomised controlled trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Frozen or Fresh Embryos for IVF Transfer?
Embolism Following IVF: Does Fresh or Frozen-Thawed Transfer Matter?
ASRM guidance: ART and recommended number of embryos to transfer

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site